Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area
Over the past years, radiotherapy techniques have changed significantly. The impact of these changes in the management of nasopharyngeal carcinoma (NPC) has not been fully evaluated.
Between 1984 and 2014, 223 NPC were diagnosed in our hospital. Prior to 2000, patients were treated with 2D treatment plan (RT2D) that evolved to 3D schemes thereafter (RT3D).
Tumors in the RT3D period showed significantly lower stages than those in the RT2D period. 5-year cause-specific survival improved from 55.7% (95% CI: 46.7–64.7%) in the RT2D period to 78.7% (95% CI: 68.7–88.7%) in the RT3D period (P = 0.006). This difference was greater for non-keratinizing NPC, where specific survival went from 63.2% (95% CI: 52.2–74.2%) to 84.4% (95% CI: 74.4–94.4%) (P = 0.014).
Recent changes in treatment strategies including concurrent chemoradiation and 3D radiotherapy may have impacted in better survival for NPC. Improved imaging techniques may have contributed by earlier detection and better treatment planning.
KeywordsNasopharyngeal carcinoma Radiation therapy IMRT Chemotherapy Chemoradiation
This work was supported by a grant from the Instituto de Salud Carlos III (FIS PI14/01918). The study was cofunded by Fondo Europeo de Desarrollo Regional (FEDER), A Way to Build Europe.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The present work is a retrospective analysis of clinical data. For this type of study formal consent is not required.
- 1.Chan JKC, Pilch BZ, Kuo TT, Wening BM, Lee AW. Tumours of the nasopharynx. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Lyon: IARC Press; 2005.Google Scholar
- 5.Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011;117(9):1874–83.CrossRefPubMedGoogle Scholar
- 8.Xu T, Zhu G, He X, Ying H, Hu C. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. Oral Oncol. 2014;50(2):71–6.CrossRefPubMedGoogle Scholar
- 10.Gregoire V, Coche E, Cosnard G, Hamoir M, Reychler H. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol. 2000;56(2):135–50.CrossRefPubMedGoogle Scholar
- 12.ICRU 50. Dose specification for reporting external beam therapy with photons and electrons. International Commission on Radiation Units and Measurements, Washington, DC;1993. Report No: 50.Google Scholar
- 19.Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer. 2010;10:558.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Boscolo-Rizzo P, Tirelli G, Mantovani M, Baggio V, Lupato V, Spinato G, et al. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice. Eur Arch Otorhinolaryngol. 2014;272(11):3491–8.CrossRefPubMedGoogle Scholar